期刊文献+

药物治疗在良性前列腺增生中的应用价值 被引量:1

Drug Treatment Application Value in Benign Prostatic Hyperplasia
原文传递
导出
摘要 老年良性前列腺增生患者采用药物进行治疗是一种比较有效的方法。目前药物治疗在临床治疗机制与治疗上进展很快,采用药物治疗良性前列腺增生已成为非常有效的治疗方法,目前正在开展药物剂型改进和不良反应降低等方面的研究工作。本文针对国内外药物治疗良性前列腺增生的进展进行初步探讨。 Elderly patients with benign prostatic hyperplasia drug treatment is a more effective method.Current drug therapy in the clinical treatment of the mechanism and treatment progressed very quickly,using the drug to treat benign prostatic hyperplasia has become a very effective method of treatment,ongoing research work on drug dosage to improve and reduce adverse reactions and other aspects.In this paper,the progress of benign prostatic hyperplasia drug treatment abroad were discussed.
作者 石岩
出处 《中国药物经济学》 2015年第4期70-71,共2页 China Journal of Pharmaceutical Economics
关键词 还原酶抑制剂 药物治疗 良性前列腺增生 Reductase inhibitor Drug therapy Benign prostatic hyperplasia
  • 相关文献

参考文献7

二级参考文献54

  • 1保列治片[J].中国新药杂志,1995,4(3):13-13. 被引量:2
  • 2吕坚伟,周立新,冷静,黄翼然,唐涌志,汤海,闵志廉,高轶.萘哌地尔与盐酸特拉唑嗪治疗良性前列腺增生的疗效与安全性评估[J].中国男科学杂志,2005,19(5):36-39. 被引量:20
  • 3那彦群,汪迪,金杰,郭应禄,薛兆英,顾方六.选择性α_(1a)受体阻断剂治疗前列腺增生症[J].中华泌尿外科杂志,1996,17(6):327-329. 被引量:22
  • 4Chapple CR. Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity [J]? BrJ Urol, 1995, 76 (Suppl 1): 47-55.
  • 5Niebch G, Locher M, BorbeH O. Metabolic fate of the novel antihypertensive drug naftopidil [J]. Arzneimittelforschung, 1991, 41 (10): 1027-1032.
  • 6Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes [J].Annu RevBiochem, 1994, 63 (1): 25-61.
  • 7Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia [J]. Urology, 2002, 60: 434-441.
  • 8O'leary MP, Roehrborn C, Andriole G, et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor [J]. BJU Int, 2003, 92 (3): 262-266.
  • 9Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia [J]. Urology, 2004, 63 (4): 709-715.
  • 10McConnell JD. Epidemiology, etiology, pathophysiology, and diagnosis of benign prostatic hyperplasia. In:Walsh PC, Sfamey TA. Campbell's Urology [M]. 7th ed. Philadelphia: Saunders, 1998:1429-1452.

共引文献46

同被引文献16

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部